Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Living Cell Technologies ( (AU:1AI) ).
Algorae Pharmaceuticals has outlined plans for a new capital raising via a placement or similar issue of securities on the ASX. The company intends to issue up to 89,350,001 fully paid ordinary shares and 11,000,000 options exercisable at $0.014 each, with an expiry date of 1 December 2029.
The proposed securities are scheduled for issue on 2 April 2026, subject to ASX processes and listing rules. This capital initiative is expected to strengthen Algorae Pharmaceuticals’ funding base, providing additional resources to support its operations and strategic objectives in the competitive pharmaceuticals market.
The most recent analyst rating on (AU:1AI) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Living Cell Technologies stock, see the AU:1AI Stock Forecast page.
More about Living Cell Technologies
Algorae Pharmaceuticals Limited is an Australia-based biotechnology company listed on the ASX under the code 1AI. The company operates in the pharmaceuticals sector and accesses capital markets through equity issuances to fund its ongoing activities and growth initiatives.
YTD Price Performance: 28.57%
Average Trading Volume: 1,488,699
Technical Sentiment Signal: Buy
Current Market Cap: A$31.7M
For an in-depth examination of 1AI stock, go to TipRanks’ Overview page.